Researchers from Ambrx Inc. and Novocodex Biopharmaceuticals Co. Ltd. presented preclinical data for ARX-305, a next-generation anti-CD70 antibody-drug conjugate (ADC), being developed for the treatment of CD70-expressing cancers.
Myeloid cells expressing LILRB2 are abundant in the tumor microenvironment and can both drive cancer progression and hinder immune responses. Thus, targeting LILRB2 offers a potential strategy to boost immune-based cancer therapies, as it counteracts their suppressive effects on pro-inflammatory pathways.
Researchers from Genequantum Healthcare (Suzhou) Co. Ltd. have presented the first preclinical data on GQ-1007, an antibody immune agonist conjugate (AIAC) targeting HER2, for the treatment of cancer. GQ-1007 is an anti-HER2 antibody conjugated via Genequantum’s highly stable linker and enzymatic conjugation technology to a Toll-like receptor 7/8 (TLR7/8) agonist.
Briacell Therapeutics Corp. has received IND clearance from the FDA to begin clinical studies with Bria-OTS, the first generation of the company’s personalized off-the-shelf cellular immunotherapy for breast cancer.
CSPC Pharmaceutical Group Ltd.’s SYS-6011 has been cleared by China’s National Medical Products Administration (NMPA) to enter clinical trials in China for solid tumors.
At the Society for Immunotherapy of Cancer’s annual meeting, researchers from Tallac Therapeutics Inc. reported the discovery of TAC-003, a novel Toll-like receptor 9 (TLR9) agonist and Nectin-4-specific antibody conjugate, being developed as cancer immunotherapy candidate.
RSS
